Circadian Timing in Cancer Treatments
Tóm tắt
The circadian timing system is composed of molecular clocks, which drive 24-h changes in xenobiotic metabolism and detoxification, cell cycle events, DNA repair, apoptosis, and angiogenesis. The cellular circadian clocks are coordinated by endogenous physiological rhythms, so that they tick in synchrony in the host tissues that can be damaged by anticancer agents. As a result, circadian timing can modify 2- to 10-fold the tolerability of anticancer medications in experimental models and in cancer patients. Improved efficacy is also seen when drugs are given near their respective times of best tolerability, due to (a) inherently poor circadian entrainment of tumors and (b) persistent circadian entrainment of healthy tissues. Conversely, host clocks are disrupted whenever anticancer drugs are administered at their most toxic time. On the other hand, circadian disruption accelerates experimental and clinical cancer processes. Gender, circadian physiology, clock genes, and cell cycle critically affect outcome on cancer chronotherapeutics. Mathematical and systems biology approaches currently develop and integrate theoretical, experimental, and technological tools in order to further optimize and personalize the circadian administration of cancer treatments.
Từ khóa
Tài liệu tham khảo
1. DeVita VT, Lawrence TS, Rosenberg SA. 2008. De Vita, Hellman and Rosenberg's Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott. 3035 pp.
2. Rowland M. 2009. Clinical Pharmacokinetics. Concepts and Applications. Philadelphia: Lippincott Williams & Wilkins. 704 pp.
Mormont MC, 2000, Clin. Cancer Res., 6, 3038
19. Touitou Y, Haus E. 1994. Biologic Rhythms in Clinical and Laboratory Medicine. Berlin: Springer-Verlag. 730 pp.
Okyar A, 2008, Trends in Cell Cycle Research, 293
Lévi F, 1988, Annu. Rev. Chronopharmacol., 4, 283
Boughattas NA, 1990, J. Pharmacol. Exp. Ther., 255, 672
Levi F, 1985, Cancer Treat. Rep., 69, 1443
Tampellini M, 1998, Cancer Res., 58, 3896
59. Boughattas NA. 1989. Rythmes de la Pharmacocinétique et de la Pharmacodinamie de Trois agents Anticancéreux (Cisplatine, Oxaliplatine et Carboplatine) Chez la Souris: Approche de Leurs Régulations. Paris: Univ. Paris VII. 255 pp.
Boughattas NA, 1989, Cancer Res., 49, 3362
Klein F, 1988, Annu. Rev. Chronopharmacol., 5, 367
Sothern R, 1988, Annu. Rev. Chronopharmacol., 5, 385
Granda TG, 2001, Cancer Res., 61, 1996
Radzialowski FM, 1968, J. Pharmacol. Exp. Ther., 163, 229
Belanger P, 1988, Annu. Rev. Chronopharmacol., 4, 1
Lévi F, 2003, Fluoropyrimidines in Cancer Therapy, 107
Ohdo S, 1997, J. Pharmacol. Exp. Ther., 283, 1383
82. Ahowesso C, Li XM, Guettier C, Bareggi S, Filipski E, et al. 2009. Preclinical model for the personalization of cancer chronotherapeutics. Presented at Congr. Eur. Biol. Rhythm Soc., 11th, Strasbourg, France
84. Okyar A, Filipski E, Dulong S, Ahowesso C, Li X, et al. 2009. Rhythmic intestinal drug elimination via ABC transporters: a potential determinant of anticancer drugs chronopharmacology. Presented at Congr. Eur. Biol. Rhythm Soc., 11th, Strasbourg, France
Haus E, 1974, Chronobiologia, 1, 270
Blumenthal RD, 2001, Clin. Cancer Res., 7, 3178
Takane H, 2000, J. Pharmacol. Exp. Ther., 294, 746
Efimov ML, 1992, Vopr. Onkol., 38, 1085
Koyanagi S, 2003, Cancer Res., 63, 7277
Pirovano M, 2007, Impact on therapeutic index of a chronomodulated infusion at conventional doses of oxaliplatin (OHP), 5-fluorouracil (5-FU) and folinic acid (AF) in not previously treated metastatic colorectal cancer patients: a multicentric observational study
Nowakowska-Dulawa E, 1990, Chronobiologia, 17, 27
Koren G, 1990, Am. J. Dis. Child, 144, 1135
Muggia FM, 1996, Clin. Cancer Res., 2, 1461
Vassal G, 1993, Cancer Res., 53, 1534
Petit E, 1988, Cancer Res., 48, 1676
Squalli A, 1989, Annu. Rev. Chronopharmacol., 5, 393
Focan C, 1989, Bull. Cancer, 76, 909
Takimoto CH, 1999, Clin. Cancer Res., 5, 1347
150. Giacchetti S, Curé H, Adenis A, Tubiana N, Vernillet L, et al. 2001. Randomized multicenter trial of irinotecan (CPT) chronomodulated (chrono) versus standard (std) infusion in patients (pts) with metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol., 20th, San Francisco (abstr. 2218)
161. Bjarnason G, Seth A, Wang Z, Blanas N, Straume M, Martino T. 2007. Diurnal rhythms (DR) in gene expression in human oral mucosa: implications for gender differences and toxicity, response and survival and optimal timing of targeted therapy (Rx). Presented at Annu. Meet. Am. Soc. Clin. Oncol., 43rd, Chicago
Harris BE, 1990, Cancer Res., 50, 197
Filipski E, 1999, J. Pharmacol. Exp. Ther., 289, 231
184. Lévi F, Innominato P, Poncet A, Moreau T, Iacobelli S, et al. 2009. Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT). Presented at Annu. Meet. Am. Soc. Clin. Oncol., 45th, Orlando, FL (Abstract 4112)
187. Friberg G, Schumm P, Ratain MJ, Schilsky RL, Fleming GF. 2004. Circadian variations in plasma 5-fluorouracil (5-FU) levels during 24-hour infusions. Presented at Annu. Meet. Am. Soc. Clin. Oncol., 40th New Orleans, LA
Dulong S, 2009, Human in vitro model of molecular chronopharmacology of anticancer drug irinotecan
Hrushesky WJ, 1982, Cancer Res., 42, 945
215. Clairambault J. 2009. Modelling physiological and pharmacological control on cell proliferation to optimize cancer treatments. Mathematical Modelling of Natural Phenomena (MMNP) published online. DOI: 10.1051/mmnp/20094302
Popovic P, 1982, Biomedical Thermology, 185
Harris BE, 1989, Cancer Res., 49, 6610
Peters GJ, 1987, In Vivo, 1, 113
Zhang R, 1993, Cancer Res., 53, 2816
Rose WC, 1978, Cancer Treat. Rep., 62, 1337
Levi F, 1980, Chronobiologia, 7, 227
Halberg F, 1980, Int. J. Chronobiol., 7, 85
Scheving LE, 1980, Cancer Res., 40, 1511
Levi F, 1988, Exp. Hematol., 16, 696
Levi F, 1995, Bull. Cancer, 82, S29
241. Halberg F, Gupta B, Haus E, Halberg E, Deka A, et al. 1977. Steps toward a cancer chronopolytherapy. Presented at Int. Congr. Therapeutics, 14th, Montpellier, France
Mormont MC, 1986, Annu. Rev. Chronopharmacol., 3, 187
Scheving LE, 1977, Cancer Res., 37, 3648
Badran AF, 1965, J. Natl. Cancer Inst., 35, 285
Snyder NK, 1981, Chronobiologia, 8, 33
247. Sothern RB, Rosene G, Nelson W, Jovonovich JA, Wurcher T, Halberg F. 1977. Circadian rhythm in tolerance of melphalan by mice. Presented at Int. Conf. Int. Soc. Chronobiol., 12th, Milano, Italy
Levi F, 1982, Cancer Treat. Rep., 66, 1933
Levi FA, 1982, Cancer Res., 42, 950
255. Hrushesky W, Langevin T, Nygaard S, Young J, Roemeling R. 1987. Circadian stipulation required for reduction of variability in TNF toxicity/efficacy. Proc. Int. Conf. on TNF and Related Cytotoxins, Heidelberg, Germany
Lévi F, 1981, Chronopharmacology, 363